No Data
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Earnings Are Weaker Than They Seem
Financial Morning Post: The first batch of active equity funds' third-quarter reports are released, leveraged funds continue to enter the market, and margin trading balance has increased for seven consecutive trading days.
【Highlights】A-shares are expected to welcome hundreds of billions of incremental funds. After the accelerated implementation of two major innovative mmf policy tools, all parties in the market are speeding up their participation and advancing related matters. On the 18th, the People's Bank of China announced the official launch of SFISF, with an initial operation scale of 500 billion yuan. The central bank will conduct operations in batches according to the needs of participating institutions. The first batch of 20 securities and fund companies have been approved to participate, with the initial application quota exceeding 200 billion yuan. Subsequently, institutions responded quickly and actively promoted the landing of SFISF business. Starting this Monday (21st), China International Capital Corporation and GTJA.
Nootech: Third quarter report 2024
Nuotai Biology (688076.SH): Compound pike sulfate sodium granules obtain pharmaceutical registration certificate.
On October 14, Geelonghui reported that Autobio Diagnostics (688076.SH) recently received the "Pharmaceutical Registration Certificate" for the compound sodium picosulfate granules approved and issued by the National Medical Products Administration. Compound sodium picosulfate granules are a compound preparation composed of sodium picosulfate, magnesium oxide, and citric acid. They are used before radiographic examination, endoscopic examination, or surgery to clean the intestines and are not used as routine laxatives.
Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) Seems To Use Debt Quite Sensibly
Earnings Not Telling The Story For Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (SHSE:688076) After Shares Rise 26%No Data
No Data
